Drug-target network

Muhammed A. Yildirim, Kwang-Il Goh, Michael E. Cusick, A. L. Barabási, Marc Vidal

Research output: Contribution to journalArticle

1120 Citations (Scopus)

Abstract

The global set of relationships between protein targets of all drugs and all disease-gene products in the human protein-protein interaction or 'interactome' network remains uncharacterized. We built a bipartite graph composed of US Food and Drug Administration-approved drugs and proteins linked by drug-target binary associations. The resulting network connects most drugs into a highly interlinked giant component, with strong local clustering of drugs of similar types according to Anatomical Therapeutic Chemical classification. Topological analyses of this network quantitatively showed an overabundance of 'follow-on' drugs, that is, drugs that target already targeted proteins. By including drugs currently under investigation, we identified a trend toward more functionally diverse targets improving polypharmacology. To analyze the relationships between drug targets and disease-gene products, we measured the shortest distance between both sets of proteins in current models of the human interactome network. Significant differences in distance were found between etiological and palliative drugs. A recent trend toward more rational drug design was observed.

Original languageEnglish
Pages (from-to)1119-1126
Number of pages8
JournalNature Biotechnology
Volume25
Issue number10
DOIs
Publication statusPublished - 2007 Oct 1

Fingerprint

Proteins
Pharmaceutical Preparations
Genes
Polypharmacology
Drug Design
United States Food and Drug Administration
Cluster Analysis

ASJC Scopus subject areas

  • Microbiology

Cite this

Yildirim, M. A., Goh, K-I., Cusick, M. E., Barabási, A. L., & Vidal, M. (2007). Drug-target network. Nature Biotechnology, 25(10), 1119-1126. https://doi.org/10.1038/nbt1338

Drug-target network. / Yildirim, Muhammed A.; Goh, Kwang-Il; Cusick, Michael E.; Barabási, A. L.; Vidal, Marc.

In: Nature Biotechnology, Vol. 25, No. 10, 01.10.2007, p. 1119-1126.

Research output: Contribution to journalArticle

Yildirim, MA, Goh, K-I, Cusick, ME, Barabási, AL & Vidal, M 2007, 'Drug-target network', Nature Biotechnology, vol. 25, no. 10, pp. 1119-1126. https://doi.org/10.1038/nbt1338
Yildirim MA, Goh K-I, Cusick ME, Barabási AL, Vidal M. Drug-target network. Nature Biotechnology. 2007 Oct 1;25(10):1119-1126. https://doi.org/10.1038/nbt1338
Yildirim, Muhammed A. ; Goh, Kwang-Il ; Cusick, Michael E. ; Barabási, A. L. ; Vidal, Marc. / Drug-target network. In: Nature Biotechnology. 2007 ; Vol. 25, No. 10. pp. 1119-1126.
@article{cb1f0a4e0798408987c62d830cfe478a,
title = "Drug-target network",
abstract = "The global set of relationships between protein targets of all drugs and all disease-gene products in the human protein-protein interaction or 'interactome' network remains uncharacterized. We built a bipartite graph composed of US Food and Drug Administration-approved drugs and proteins linked by drug-target binary associations. The resulting network connects most drugs into a highly interlinked giant component, with strong local clustering of drugs of similar types according to Anatomical Therapeutic Chemical classification. Topological analyses of this network quantitatively showed an overabundance of 'follow-on' drugs, that is, drugs that target already targeted proteins. By including drugs currently under investigation, we identified a trend toward more functionally diverse targets improving polypharmacology. To analyze the relationships between drug targets and disease-gene products, we measured the shortest distance between both sets of proteins in current models of the human interactome network. Significant differences in distance were found between etiological and palliative drugs. A recent trend toward more rational drug design was observed.",
author = "Yildirim, {Muhammed A.} and Kwang-Il Goh and Cusick, {Michael E.} and Barab{\'a}si, {A. L.} and Marc Vidal",
year = "2007",
month = "10",
day = "1",
doi = "10.1038/nbt1338",
language = "English",
volume = "25",
pages = "1119--1126",
journal = "Biotechnology",
issn = "0733-222X",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Drug-target network

AU - Yildirim, Muhammed A.

AU - Goh, Kwang-Il

AU - Cusick, Michael E.

AU - Barabási, A. L.

AU - Vidal, Marc

PY - 2007/10/1

Y1 - 2007/10/1

N2 - The global set of relationships between protein targets of all drugs and all disease-gene products in the human protein-protein interaction or 'interactome' network remains uncharacterized. We built a bipartite graph composed of US Food and Drug Administration-approved drugs and proteins linked by drug-target binary associations. The resulting network connects most drugs into a highly interlinked giant component, with strong local clustering of drugs of similar types according to Anatomical Therapeutic Chemical classification. Topological analyses of this network quantitatively showed an overabundance of 'follow-on' drugs, that is, drugs that target already targeted proteins. By including drugs currently under investigation, we identified a trend toward more functionally diverse targets improving polypharmacology. To analyze the relationships between drug targets and disease-gene products, we measured the shortest distance between both sets of proteins in current models of the human interactome network. Significant differences in distance were found between etiological and palliative drugs. A recent trend toward more rational drug design was observed.

AB - The global set of relationships between protein targets of all drugs and all disease-gene products in the human protein-protein interaction or 'interactome' network remains uncharacterized. We built a bipartite graph composed of US Food and Drug Administration-approved drugs and proteins linked by drug-target binary associations. The resulting network connects most drugs into a highly interlinked giant component, with strong local clustering of drugs of similar types according to Anatomical Therapeutic Chemical classification. Topological analyses of this network quantitatively showed an overabundance of 'follow-on' drugs, that is, drugs that target already targeted proteins. By including drugs currently under investigation, we identified a trend toward more functionally diverse targets improving polypharmacology. To analyze the relationships between drug targets and disease-gene products, we measured the shortest distance between both sets of proteins in current models of the human interactome network. Significant differences in distance were found between etiological and palliative drugs. A recent trend toward more rational drug design was observed.

UR - http://www.scopus.com/inward/record.url?scp=35148838537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35148838537&partnerID=8YFLogxK

U2 - 10.1038/nbt1338

DO - 10.1038/nbt1338

M3 - Article

C2 - 17921997

AN - SCOPUS:35148838537

VL - 25

SP - 1119

EP - 1126

JO - Biotechnology

JF - Biotechnology

SN - 0733-222X

IS - 10

ER -